Post-Ensartinib Outcomes in Refractory Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

被引：1
|
作者：
Kim, H. [1 ]
Vu, P. [2 ]
Harrow, K. [3 ]
Liang, C. [4 ]
Selvaggi, G. [3 ]
Weihe, E. [2 ]
Mitchell, W. [2 ]
Bazhenova, L. [2 ]
Patel, S. [2 ]
机构：
[1] Univ Calif San Diego, La Jolla, CA USA
[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA USA
[3] Xcovery Holdings Inc, Palm Beach Gardens, AL USA
[4] Xcovery Holdings Inc, Palm Beach Gardens, FL USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
NSCLC; ALK; ensartinib;
D O I：
10.1016/j.jtho.2019.08.1208
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.14-57
引用
收藏
页码：S577 / S578
页数：2
相关论文
共 50 条
  • [21] Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer
    Hou, Donghui
    Zheng, Xiaomin
    Song, Wei
    Liu, Xiaoqing
    Wang, Sicong
    Zhou, Lina
    Tao, Xiuli
    Lv, Lv
    Sun, Qi
    Jin, Yujing
    Zhang, Zewei
    Ding, Lieming
    Wu, Ning
    Zhao, Shijun
    THORACIC CANCER, 2021, 12 (17) : 2388 - 2399
  • [22] eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
    Horn, L.
    Wu, Y-L.
    Reck, M.
    Liang, C.
    Tan, F.
    Harrow, K.
    Oertel, V.
    Dukart, G.
    Mok, T. S. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S116 - S116
  • [23] eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients
    Horn, Leora
    Wu, Yi-Long
    Reck, Martin
    Wakelee, Heather A.
    Liang, Chris
    Tan, Fenlai
    Harrow, Kimberly
    Oertel, Vance
    Dukart, Gary
    Mok, Tony
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
    Lin, H.
    Pan, X.
    Huang, H.
    Salvatore, G.
    Clarke, S.
    West, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S617 - S617
  • [25] DETECTION OF ANAPLASTIC LYMPHOMA KINASE (ALK) GENE REARRANGEMENT IN NON-SMALL CELL LUNG CANCER (NSCLC): A GLANCE AT "BORDERLINE" CASES
    von Laffert, M.
    Berg, E.
    Lenze, D.
    Lohneis, P.
    Hummel, M.
    Dietel, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 390 - 390
  • [26] Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer
    Kim, Hee Kyung
    Ahn, Myung-Ju
    EXPERT OPINION ON ORPHAN DRUGS, 2018, 6 (04): : 253 - 258
  • [27] Review of Therapeutic Strategies for Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
    Fukui, Takafumi
    Tachihara, Motoko
    Nagano, Tatsuya
    Kobayashi, Kazuyuki
    CANCERS, 2022, 14 (05)
  • [28] Role of radiotherapy in management of brain metastases in anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC): A single-center retrospective study
    Zhao, Y.
    Zhang, B.
    Zhang, Y.
    Wang, S.
    Qian, J.
    Han, B-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] Pharmacokinetics of ensartinib in advanced solid tumors and anaplastic lymphoma kinase-positive non-small cell lung cancer
    Xu, Y.
    Ji, D.
    Pan, P.
    Li, T.
    Han, L-X.
    Zhang, Z.
    Wang, Y.
    Li, H.
    Chen, X-F.
    Zheng, X-J.
    Xu, L.
    Liu, H-X.
    Meng, Q-H.
    Wang, M-Z.
    Zheng, Q-S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1086 - S1086
  • [30] Long Term Efficacy and Safety of Ensartinib in Pre-Treated Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients (eXalt2)
    Leal, T.
    Wakelee, H.
    Reckamp, K. L.
    Chiappori, A.
    Oxnard, G. R.
    Waqar, S. N.
    Patel, S. P.
    Blumenschein, G. R.
    Neal, J. W.
    Harrow, K.
    Holzhausen, A.
    Selvaggi, G.
    Zhou, J.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1171 - S1172
12345